Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DEMGEN · Entity 4316 | Director | June 28, 2017 | June 30, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viridian Therapeutics, Inc.\DE
Report date June 28, 2017 · Filed June 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.06 · Expires 2027-06-27 | Direct | 12,000 |
Reported balance
After 2017-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-28 · Grant · Acquired 12,000 · Balance 12,000 F1: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARRAY BIOPHARMA INC
Report date July 30, 2019 · Filed July 30, 2019
Section 16 reporting ended · disclosed 2019-07-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,000 |
Ending reported balance
After 2019-07-30 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-07-30 · Other · Disposed 22,635 · Balance 70,085 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was validly tendered for $48.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. Row 2 · 2019-07-30 · Disposition to issuer · Disposed 85 · Balance 70,000 F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3: On June 14, 2019, the Company entered into a Merger Agreement with Pfizer and Purchaser. Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. Row 3 · 2019-07-30 · Disposition to issuer · Disposed 5,000 · Balance 65,000 F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3: On June 14, 2019, the Company entered into a Merger Agreement with Pfizer and Purchaser. Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F4: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 45,000 |
Reported balance
After 2019-07-30 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2019-07-30 · Other · Disposed 20,000 · Balance 45,000 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was validly tendered for $48.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F5: Held in trust for the benefit of the Reporting Person's minor children. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 30,000 |
Reported balance
After 2019-07-30 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2019-07-30 · Other · Disposed 15,000 · Balance 30,000 F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3: On June 14, 2019, the Company entered into a Merger Agreement with Pfizer and Purchaser. Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F6: Held by BV Partners III Profit Sharing account for the benefit of the Reporting Person. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2019-07-30 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2019-07-30 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3: On June 14, 2019, the Company entered into a Merger Agreement with Pfizer and Purchaser. Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F6: Held by BV Partners III Profit Sharing account for the benefit of the Reporting Person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.55 · Expires 2028-10-25 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-07-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F8: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F7: The option provided for vesting in four equal annual installments beginning on October 25, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was validly tendered for $48.00 per share in cash, without interest and subject to any required withholding of taxes.
F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.
F3: On June 14, 2019, the Company entered into a Merger Agreement with Pfizer and Purchaser. Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.
F4: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.
F5: Held in trust for the benefit of the Reporting Person's minor children.
F6: Held by BV Partners III Profit Sharing account for the benefit of the Reporting Person.
F7: The option provided for vesting in four equal annual installments beginning on October 25, 2019.
F8: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 30, 2019 Filed Jul 30, 2019 20:03 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $14.55 | Not disclosed |
DisclosureSEC source: 0001209191-19-043780 · doc4.xml · derivative · entry 7 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2028-10-25 F8 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F7 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on October 25, 2019. Read SEC document |
| July 30, 2019 Filed Jul 30, 2019 20:03 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Disposition to issuerCommon Stock | 30,000 | $48.00 | $1,440,000.00 |
DisclosureSEC source: 0001209191-19-043780 · doc4.xml · nonDerivative · entry 6 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F2 · kind: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3 · kind: On June 14, 2019, the Company entered into a Merger Agreement with Pfizer and Purchaser. Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F6 · ownership.nature: Held by BV Partners III Profit Sharing account for the benefit of the Reporting Person. Read SEC document |
| July 30, 2019 Filed Jul 30, 2019 20:03 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | OtherCommon Stock | 15,000 | $48.00 | $720,000.00 |
DisclosureSEC source: 0001209191-19-043780 · doc4.xml · nonDerivative · entry 5 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 30,000 F2 · kind: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3 · kind: On June 14, 2019, the Company entered into a Merger Agreement with Pfizer and Purchaser. Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F6 · ownership.nature: Held by BV Partners III Profit Sharing account for the benefit of the Reporting Person. Read SEC document |
| July 30, 2019 Filed Jul 30, 2019 20:03 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | OtherCommon Stock | 20,000 | $48.00 | $960,000.00 |
DisclosureSEC source: 0001209191-19-043780 · doc4.xml · nonDerivative · entry 4 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 45,000 F1 · kind: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was validly tendered for $48.00 per share in cash, without interest and subject to any required withholding of taxes. F2 · kind: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F5 · ownership.nature: Held in trust for the benefit of the Reporting Person's minor children. Read SEC document |
| July 30, 2019 Filed Jul 30, 2019 20:03 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Disposition to issuerCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043780 · doc4.xml · nonDerivative · entry 3 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 F2 · kind: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3 · kind: On June 14, 2019, the Company entered into a Merger Agreement with Pfizer and Purchaser. Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F4 · price: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU. Read SEC document |
| July 30, 2019 Filed Jul 30, 2019 20:03 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Disposition to issuerCommon Stock | 85 | $48.00 | $4,080.00 |
DisclosureSEC source: 0001209191-19-043780 · doc4.xml · nonDerivative · entry 2 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F2 · kind: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3 · kind: On June 14, 2019, the Company entered into a Merger Agreement with Pfizer and Purchaser. Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. Read SEC document |
| July 30, 2019 Filed Jul 30, 2019 20:03 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | OtherCommon Stock | 22,635 | $48.00 | $1,086,480.00 |
DisclosureSEC source: 0001209191-19-043780 · doc4.xml · nonDerivative · entry 1 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,085 F1 · kind: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was validly tendered for $48.00 per share in cash, without interest and subject to any required withholding of taxes. F2 · kind: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 19:14 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $10.47 | $0.00 |
DisclosureSEC source: 0001562180-19-000863 · primarydocument.xml · derivative · entry 6 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2027-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The options vested on October 26, 2018. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 19:14 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | SaleCommon Stock | 5,000 | $20.85 | $104,261.00 |
DisclosureSEC source: 0001562180-19-000863 · primarydocument.xml · nonDerivative · entry 4 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,000 F2 · shares: The sale was made by the Reporting Person as custodian for his son under the Colorado Uniform Gifts to Minors Act. F5 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $20.805 to $20.864. Details of actual prices for shares sold are available from the Reporting Person upon request. F4 · balance_after: Comprised of shares of common stock in trust for the benefit of the Reporting Person's minor children. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 19:14 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | SaleCommon Stock | 5,000 | $20.82 | $104,120.50 |
DisclosureSEC source: 0001562180-19-000863 · primarydocument.xml · nonDerivative · entry 3 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 25,000 F2 · shares: The sale was made by the Reporting Person as custodian for his son under the Colorado Uniform Gifts to Minors Act. F3 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $20.785 to $20.834. Details of actual prices for shares sold are available from the Reporting Person upon request. F4 · balance_after: Comprised of shares of common stock in trust for the benefit of the Reporting Person's minor children. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 19:14 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | SaleCommon Stock | 25,000 | $20.51 | $512,692.50 |
DisclosureSEC source: 0001562180-19-000863 · primarydocument.xml · nonDerivative · entry 2 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,720 F1 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $20.50 to $20.58. Details of actual prices for shares sold are available from the Reporting Person upon request. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 19:14 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 25,000 | $10.47 | $261,750.00 |
DisclosureSEC source: 0001562180-19-000863 · primarydocument.xml · nonDerivative · entry 1 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2018 Filed Oct 29, 2018 18:10 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004315 · primarydocument.xml · derivative · entry 5 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The RSUs vested and were settled in common stock on October 26, 2018. F5 · derivative.expiration_date: The RSUs vested and were settled in common stock on October 26, 2018. Read SEC document |
| October 26, 2018 Filed Oct 29, 2018 18:10 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-18-004315 · primarydocument.xml · nonDerivative · entry 1 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by Array BioPharma Inc. ("Array") on October 26, 2017, as a result of the vesting of all such RSUs. F1 · price: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by Array BioPharma Inc. ("Array") on October 26, 2017, as a result of the vesting of all such RSUs. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 18:10 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004315 · primarydocument.xml · derivative · entry 4 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F4 · derivative.exercise_date: RSUs awarded to the reporting person for no additional cash consideration and each represents a contingent right to receive one share of common stock. The RSUs vest in full and will be settled in common stock on October 25, 2019, subject to continued service on Array's board of directors. F4 · derivative.expiration_date: RSUs awarded to the reporting person for no additional cash consideration and each represents a contingent right to receive one share of common stock. The RSUs vest in full and will be settled in common stock on October 25, 2019, subject to continued service on Array's board of directors. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 18:10 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001562180-18-004315 · primarydocument.xml · derivative · entry 3 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-10-25 F3 · derivative.exercise_date: The options vest in full on October 25, 2019, subject to continued service on Array's board of directors. Read SEC document |
| July 06, 2018 Filed Jul 6, 2018 16:06 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-18-041857 · doc4.xml · derivative · entry 6 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2018 Filed Jul 6, 2018 16:06 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001209191-18-041857 · doc4.xml · derivative · entry 5 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2024-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2018 Filed Jul 6, 2018 16:06 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | SaleCommon Stock | 50,000 | $17.45 | $872,500.00 |
DisclosureSEC source: 0001209191-18-041857 · doc4.xml · nonDerivative · entry 3 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,720 F1 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $17.45 to $17.461. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document |
| July 06, 2018 Filed Jul 6, 2018 16:06 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 25,000 | $5.95 | $148,750.00 |
DisclosureSEC source: 0001209191-18-041857 · doc4.xml · nonDerivative · entry 2 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2018 Filed Jul 6, 2018 16:06 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 25,000 | $5.13 | $128,250.00 |
DisclosureSEC source: 0001209191-18-041857 · doc4.xml · nonDerivative · entry 1 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 17:27 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0001562180-18-000729 · primarydocument.xml · derivative · entry 6 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2024-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 17:27 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001562180-18-000729 · primarydocument.xml · derivative · entry 5 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2023-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 17:27 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | SaleCommon Stock | 50,000 | $17.01 | $850,500.00 |
DisclosureSEC source: 0001562180-18-000729 · primarydocument.xml · nonDerivative · entry 3 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,720 F1 · price: The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 17:27 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 25,000 | $3.87 | $96,750.00 |
DisclosureSEC source: 0001562180-18-000729 · primarydocument.xml · nonDerivative · entry 2 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 17:27 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 25,000 | $5.60 | $140,000.00 |
DisclosureSEC source: 0001562180-18-000729 · primarydocument.xml · nonDerivative · entry 1 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 27, 2017 Filed Oct 27, 2017 16:32 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003345 · primarydocument.xml · derivative · entry 5 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: RSUs awarded to the reporting person on October 27, 2016 for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The units vested and were settled in stock on October 27, 2017. Read SEC document |
| October 27, 2017 Filed Oct 27, 2017 16:32 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 5,000 | $10.47 | $52,350.00 |
DisclosureSEC source: 0001562180-17-003345 · primarydocument.xml · nonDerivative · entry 1 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by the Issuer on October 27, 2016 as a result of the vesting of all such RSUs. Read SEC document |
| October 26, 2017 Filed Oct 27, 2017 16:32 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003345 · primarydocument.xml · derivative · entry 4 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F3 · derivative.expiration_date: . RSUs awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The units vest and will be settled in stock on October 26, 2018, subject to continued service on Array's board of directors. Read SEC document |
| October 26, 2017 Filed Oct 27, 2017 16:32 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $10.47 | $0.00 |
DisclosureSEC source: 0001562180-17-003345 · primarydocument.xml · derivative · entry 3 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-10-26 Read SEC document |
| September 29, 2017 Filed Sep 29, 2017 18:22 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option · Derivative | 45,000 | $0.00 Strike: $10.58 | $0.00 |
DisclosureSEC source: 0001562180-17-003064 · primarydocument.xml · derivative · entry 4 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2017-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form 4 is reporting the exercise by the reporting person of an option scheduled to expire on November 1, 2017 and the sale of a portion of the option shares to satisfy payment of the option exercise price. F3 · derivative.exercise_date: The option vested in 3 equal annual installments beginning on November 1, 2008. Read SEC document |
| September 29, 2017 Filed Sep 29, 2017 18:22 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | SaleCommon Stock | 38,865 | $12.31 | $478,428.15 |
DisclosureSEC source: 0001562180-17-003064 · primarydocument.xml · nonDerivative · entry 2 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,720 Read SEC document |
| September 29, 2017 Filed Sep 29, 2017 18:22 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 45,000 | $10.58 | $476,100.00 |
DisclosureSEC source: 0001562180-17-003064 · primarydocument.xml · nonDerivative · entry 1 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form 4 is reporting the exercise by the reporting person of an option scheduled to expire on November 1, 2017 and the sale of a portion of the option shares to satisfy payment of the option exercise price. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 17:24 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $12.06 | $0.00 |
DisclosureSEC source: 0001209191-17-042575 · doc4.xml · derivative · entry 1 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-27 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 21:41 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option · Derivative | 20,000 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001562180-17-001461 · primarydocument.xml · derivative · entry 7 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 21:41 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $3.69 | $0.00 |
DisclosureSEC source: 0001562180-17-001461 · primarydocument.xml · derivative · entry 6 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in 2 equal annual installments beginning on April 25, 2013. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 21:41 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | SaleCommon Stock | 45,000 | $8.92 | $401,400.00 |
DisclosureSEC source: 0001562180-17-001461 · primarydocument.xml · nonDerivative · entry 4 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,585 F1 · price: The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 21:41 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 20,000 | $4.36 | $87,200.00 |
DisclosureSEC source: 0001562180-17-001461 · primarydocument.xml · nonDerivative · entry 3 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 21:41 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 25,000 | $3.69 | $92,250.00 |
DisclosureSEC source: 0001562180-17-001461 · primarydocument.xml · nonDerivative · entry 2 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2017 Filed Mar 13, 2017 18:37 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | SaleCommon Stock | 3,300 | $14.31 | $47,228.94 |
DisclosureSEC source: 0001209191-17-020291 · doc4.xml · nonDerivative · entry 2 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 463,473 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.96 to $14.645, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F2 · ownership.nature: All of the shares are held by Boulder Ventures VI, L.P. ("BV VI LP"). BV Partners VI, LLC ("BV VI LLC"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 09, 2017 Filed Mar 13, 2017 18:37 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | SaleCommon Stock | 2,500 | $14.38 | $35,961.50 |
DisclosureSEC source: 0001209191-17-020291 · doc4.xml · nonDerivative · entry 1 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 466,773 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F2 · ownership.nature: All of the shares are held by Boulder Ventures VI, L.P. ("BV VI LP"). BV Partners VI, LLC ("BV VI LLC"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 08, 2017 Filed Mar 8, 2017 17:12 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | SaleCommon Stock | 5,000 | $14.70 | $73,514.00 |
DisclosureSEC source: 0001209191-17-019319 · doc4.xml · nonDerivative · entry 3 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 469,273 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.48 to $15.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F2 · ownership.nature: All of the shares are held by Boulder Ventures VI, L.P. ("BV VI LP"). BV Partners VI, LLC ("BV VI LLC"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 17:12 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | SaleCommon Stock | 608 | $16.24 | $9,873.80 |
DisclosureSEC source: 0001209191-17-019319 · doc4.xml · nonDerivative · entry 2 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 474,273 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.21 to $16.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F2 · ownership.nature: All of the shares are held by Boulder Ventures VI, L.P. ("BV VI LP"). BV Partners VI, LLC ("BV VI LLC"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 17:12 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | SaleCommon Stock | 9,392 | $15.71 | $147,589.64 |
DisclosureSEC source: 0001209191-17-019319 · doc4.xml · nonDerivative · entry 1 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 474,881 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.20 to $16.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F2 · ownership.nature: All of the shares are held by Boulder Ventures VI, L.P. ("BV VI LP"). BV Partners VI, LLC ("BV VI LLC"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 28, 2017 Filed Feb 28, 2017 18:52 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | SaleCommon Stock | 2,258 | $13.54 | $30,580.09 |
DisclosureSEC source: 0001209191-17-015457 · doc4.xml · nonDerivative · entry 3 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 484,273 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F2 · ownership.nature: All of the shares are held by Boulder Ventures VI, L.P. ("BV VI LP"). BV Partners VI, LLC ("BV VI LLC"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 18:52 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | SaleCommon Stock | 1,500 | $13.79 | $20,686.50 |
DisclosureSEC source: 0001209191-17-015457 · doc4.xml · nonDerivative · entry 2 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 486,531 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.75 to $13.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F2 · ownership.nature: All of the shares are held by Boulder Ventures VI, L.P. ("BV VI LP"). BV Partners VI, LLC ("BV VI LLC"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 18:52 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | SaleCommon Stock | 6,500 | $14.04 | $91,252.20 |
DisclosureSEC source: 0001209191-17-015457 · doc4.xml · nonDerivative · entry 1 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 488,031 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F2 · ownership.nature: All of the shares are held by Boulder Ventures VI, L.P. ("BV VI LP"). BV Partners VI, LLC ("BV VI LLC"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 23, 2017 Filed Feb 24, 2017 19:07 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | SaleCommon Stock | 1,800 | $13.65 | $24,565.86 |
DisclosureSEC source: 0001209191-17-014537 · doc4.xml · nonDerivative · entry 2 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 494,531 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $14.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F2 · ownership.nature: All of the shares are held by Boulder Ventures VI, L.P. ("BV VI LP"). BV Partners VI, LLC ("BV VI LLC"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:07 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | SaleCommon Stock | 4,102 | $14.36 | $58,885.85 |
DisclosureSEC source: 0001209191-17-014537 · doc4.xml · nonDerivative · entry 1 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 496,331 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.28 to $14.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F2 · ownership.nature: All of the shares are held by Boulder Ventures VI, L.P. ("BV VI LP"). BV Partners VI, LLC ("BV VI LLC"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 28, 2016 Filed Apr 4, 2017 21:41 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-001461 · primarydocument.xml · nonDerivative · entry 1 LEFKOFF KYLE · CIK 0001191818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,585 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.